JP7365240B2 - 馬の掻痒の治療 - Google Patents

馬の掻痒の治療 Download PDF

Info

Publication number
JP7365240B2
JP7365240B2 JP2019571099A JP2019571099A JP7365240B2 JP 7365240 B2 JP7365240 B2 JP 7365240B2 JP 2019571099 A JP2019571099 A JP 2019571099A JP 2019571099 A JP2019571099 A JP 2019571099A JP 7365240 B2 JP7365240 B2 JP 7365240B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
eil
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019571099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020510700A (ja
JP2020510700A5 (https=
JPWO2018162577A5 (https=
Inventor
アントーニア フェッテルショッス，
ヴィクトリア フェッテルショッス，
マルティン バッハマン，
Original Assignee
ウニヴェルズィテート チューリッヒ
ウニヴェルジテート ベルン
エヴァックス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウニヴェルズィテート チューリッヒ, ウニヴェルジテート ベルン, エヴァックス アーゲー filed Critical ウニヴェルズィテート チューリッヒ
Publication of JP2020510700A publication Critical patent/JP2020510700A/ja
Publication of JP2020510700A5 publication Critical patent/JP2020510700A5/ja
Publication of JPWO2018162577A5 publication Critical patent/JPWO2018162577A5/ja
Application granted granted Critical
Publication of JP7365240B2 publication Critical patent/JP7365240B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5409—IL-5

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2019571099A 2017-03-07 2018-03-07 馬の掻痒の治療 Active JP7365240B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17159644.8 2017-03-07
EP17159644 2017-03-07
PCT/EP2018/055644 WO2018162577A1 (en) 2017-03-07 2018-03-07 Treatment of pruritus in horses

Publications (4)

Publication Number Publication Date
JP2020510700A JP2020510700A (ja) 2020-04-09
JP2020510700A5 JP2020510700A5 (https=) 2022-09-20
JPWO2018162577A5 JPWO2018162577A5 (https=) 2022-09-20
JP7365240B2 true JP7365240B2 (ja) 2023-10-19

Family

ID=58397991

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019571099A Active JP7365240B2 (ja) 2017-03-07 2018-03-07 馬の掻痒の治療

Country Status (7)

Country Link
US (3) US11207390B2 (https=)
EP (1) EP3592378A1 (https=)
JP (1) JP7365240B2 (https=)
CN (1) CN110381990A (https=)
AU (1) AU2018231413B2 (https=)
CA (1) CA3054389A1 (https=)
WO (1) WO2018162577A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3093539A1 (en) 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
AU2019236328B2 (en) 2018-03-16 2025-10-09 Zoetis Services Llc Peptide vaccines against Interleukin-31
AU2019278596A1 (en) * 2018-05-28 2020-12-24 Evax Ag Treatment of urticaria
WO2021083766A1 (en) 2019-10-29 2021-05-06 Evax Ag Treatment of pruritus in horses
BR112023016043A2 (pt) * 2021-02-22 2023-12-05 Zoetis Services Llc Modelo de prurido induzido por il-31 de cavalo
WO2023161528A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
AR133291A1 (es) * 2023-07-19 2025-09-17 Inst Pasteur De Montevideo Inmunización activa para el tratamiento de la dermatitis atópica

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004522735A (ja) 2001-01-19 2004-07-29 サイトス バイオテクノロジー アーゲー 分子抗原アレイ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003040164A2 (en) * 2001-11-07 2003-05-15 Cytos Biotechnology Ag Antigen arrays presenting il-5, il-3 or eotaxin for treatment of allergic eosinophilic diseases
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
JP6987744B2 (ja) * 2015-09-08 2022-01-05 ウニヴェルズィテート チューリッヒ 虫刺され過敏症の治療
WO2018156180A1 (en) * 2017-02-24 2018-08-30 Kindred Biosciences, Inc. Anti-il31 antibodies for veterinary use

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004522735A (ja) 2001-01-19 2004-07-29 サイトス バイオテクノロジー アーゲー 分子抗原アレイ

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Allergy and Clinical Immunology, Vol: 117, Nr: 2, Page(s): 411-417，2006年02月01日
VETERINARY DERMATOLOGY, Vol: 27, Nr: 6, Page(s): 478 - e129，2016年12月01日

Also Published As

Publication number Publication date
EP3592378A1 (en) 2020-01-15
US20250281582A1 (en) 2025-09-11
AU2018231413A1 (en) 2019-09-12
JP2020510700A (ja) 2020-04-09
CA3054389A1 (en) 2018-09-13
US20220168405A1 (en) 2022-06-02
WO2018162577A1 (en) 2018-09-13
CN110381990A (zh) 2019-10-25
US20200016248A1 (en) 2020-01-16
AU2018231413B2 (en) 2024-01-04
US11207390B2 (en) 2021-12-28

Similar Documents

Publication Publication Date Title
JP7365240B2 (ja) 馬の掻痒の治療
JP7455785B2 (ja) 虫刺され過敏症の治療
JP2020510700A5 (https=)
JP2025118600A (ja) じんましんの治療
JPWO2018162577A5 (https=)
KR20250115462A (ko) 알레르기 치료용 백신
WO2021083766A1 (en) Treatment of pruritus in horses
HK40044288A (en) Treatment of urticaria
HK1252263B (en) Treatment of insect bite hypersensitivity

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210305

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220308

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220520

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20220908

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230912

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231006

R150 Certificate of patent or registration of utility model

Ref document number: 7365240

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150